Sharh maqola

A Contemporary Systematic Review on Repartition of HPV-Positivity in Oropharyngeal Cancer Worldwide

Amanda‐Louise Fenger CarlanderDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, DenmarkKathrine Kronberg JakobsenDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, DenmarkSimone K. BendtsenDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, DenmarkMartin Garset‐ZamaniDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, DenmarkCharlotte Duch LynggaardDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, DenmarkJakob Schmidt JensenDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, DenmarkChristian GrønhøjDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, DenmarkChristian von BuchwaldDepartment of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet, 2100 Copenhagen, Capitol Region, Denmark

2021en

ABI

Annotatsiya

Significant variation in human papillomavirus (HPV) prevalence in oropharyngeal squamous cell carcinoma (OPSCC) across countries ranging from 11% in Brazil to 74% in New Zealand has been reported earlier. The aim of this study was to systematically review the most recently published studies on the occurrence of HPV in OPSCC globally. PubMed and Embase were systematically searched for articles assessing the occurrence of HPV+ OPSCC published between January 2016 and May 2021. Studies with a study period including 2015 and the following years were included. Both HPV DNA and/or p16 were accepted as indicators of HPV+ OPSCC. 31 studies were enrolled comprising 49,564 patients with OPSCC (range 12-42,024 patients per study) from 26 different countries covering all continents. The lowest occurrences of HPV+ OPSCC were observed in India (0%) and Spain (10%) and the highest occurrences were observed in Lebanon (85%) and Sweden (70%). We observed great variation in HPV prevalence in OPSCC worldwide varying from 0% to 85%. The highest occurrences of HPV+ OPSCC were found in general in Northern European countries, USA, Lebanon, China, and South Korea. We observed a trend of increase in HPV-positivity, indicating a mounting burden of HPV+ OPSCC.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.3390/v13071326

Iqtiboslar va manbalar

4 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar